Bowel obstruction have caused the death of at least two semaglutide users
As of late 2023, the FDA has received at least 33 reports of ileus from the use of drugs with semaglutide as the active ingredient. These drugs are sold in the USA under the brand names of Ozempic, Wegovy, and Rybelsus. Currently, these brands include bowel obstruction as a warning on their labels. However, this information was only added to Ozempic’s label in September 2023.
If you are currently taking a drug with semaglutide as the active ingredient, watch out for:
- Swelling
- Serious abdominal pain
- Extreme bloating, the inability to pass gas, and constipation
- Severe nausea and vomiting
- A loss of appetite
Any of these symptoms warrant a trip to a medical professional. Only a professional may accurately diagnose your condition. A proper diagnosis of bowel obstruction is the first step for those interested in filing a claim against the manufacturer of these medications.
Only patients with severe side effects, such as bowel obstruction, may be eligible for financial compensation from Novo Nordisk.
Find out if you are eligible to file a claim against the manufacturer
Diagnosis and recovery are financially, and emotionally, draining. If you’ve been diagnosed with bowel obstruction after taking semaglutide reach out to our law firm as soon as possible.
Novo Nordisk should be held liable for the trauma caused by their negligence. If you are interested in possibly receiving financial compensation, contact us and provide:
- Medical records
- A professional diagnosis
- Any proof of you having taken semaglutide, such as medication packaging with your name on it and any prescriptions you may have for Ozempic, Wegovy, or Rybelsus
Through these records, we can easily determine whether or not you are eligible to file a claim. Note that our law firm works on a contingency fee basis, which means that you only have to pay us if and when you receive compensation.